BECTON, DICKINSON AND COMPANY (NYSE:BDX) Files An 8-K Entry into a Material Definitive Agreement

BECTON, DICKINSON AND COMPANY (NYSE:BDX) Files An 8-K Entry into a Material Definitive Agreement

Story continues below

Item 1.01. Entry into a Material Definitive Agreement.

On January 17, 2017, the parties to the Five Year Credit
Agreement, dated January 29, 2016 (the Credit Agreement), among
Becton, Dickinson and Company, Citibank, N.A. as the
administrative agent, and the lenders named therein, agreed to
extend the expiration date of the Credit Agreement to January 29,
2022 in accordance with the terms of the Credit Agreement.


About BECTON, DICKINSON AND COMPANY (NYSE:BDX)

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company’s BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.

BECTON, DICKINSON AND COMPANY (NYSE:BDX) Recent Trading Information

BECTON, DICKINSON AND COMPANY (NYSE:BDX) closed its last trading session up +0.03 at 174.01 with 909,925 shares trading hands.

An ad to help with our costs